CREM005i-SS2-1GAG
This cell line is a modified version of CREM004i-SS2-1, engineered to correct the mutation in HBB(E6V). This isogenic control is unaffected. An unmodified, affected isogenic cell line, CREM004i-SS2-1, is available from WiCell.**Upon testing, the current lot of material did not meet WiCell's standards for quality, and it is therefore unavailable. WiCell is working with the Provider to obtain replacement materials for distribution. To be notified of the status of this cell line please submit your information here.
| Cell Line Alias | SCD iPSC SS.2-1-GAG, SS2-1GAG |
| Cell Type | Modified Human iPS |
| Disease | None reported |
| Genetic Alteration/Mutation | HBB(E6V) Corrected |
| Genetic Alteration/Mutation Information | A>T mutation in beta globin gene reverted to A by CRISPRs |
| Genetic Modification Keyword | Isogenic; Sickle cell |
| Sex | Female |
| Age at Collection | 32 Years |
| Ethnicity | African American |
| Ethnicity Information | Physician reported |
| Genetically Related Cell Lines | |
| Reprogramming Method | Viral transfection (Lentivirus: Oct4, Klf4, Sox2, cMyc) |
| Tissue Origin | Blood |
| Provider | Boston University and Boston Medical Center's Center for Regenerative Medicine (CReM) - Dr. Steinberg, Dr. Mostoslavsky, Dr. Murphy |
| dbGaP Data | |
| hPSCReg ID | |
| NIH Approval | |
| Pub Med Abstract | |
| Collection(s) | NHLBI Next Gen - Sickle Cell Anemia (Dr. Steinberg, Dr. Mostoslavsky, Dr. Murphy, Boston University and Boston Medical Center's Center for Regenerative Medicine) |
Current Lot Information
| Lot Number | Culture Platform | Lot Description | Passage Number | Banked By | Protocol | Product Information & Testing |
|---|---|---|---|---|---|---|
| DB66769 | mTeSR1/Matrigel | 39 | Provider | WiCell Feeder Independent Pluripotent Stem Cell Protocol |
